Compliance with herpes zoster vaccination in young and adult individuals in two regions of Italy

Parlato, Antonino; Spica, Vincenzo Romano; Ciccozzi, Massimo; Farchi, Francesca; Galle, Francesca; Onofrio, Valeria Di; Franco, Elisabetta; Liguori, Giorgio
January 2010
BMC Public Health;2010, Vol. 10 Issue 1, p333
Academic Journal
Background: The purpose of this work was to explore the knowledge and acceptance of Varicella Zoster Virus (VZV)-Herpes Zoster (HZ) vaccination in the general Italian population, where the HZ vaccine has not yet been distributed, using a prevalence study of subjects from two regions in Italy. Methods: A group of 3,173 individuals were interviewed using a questionnaire. The youngest age group (⩽ 20 year) was composed of students interviewed at university. The middle age group (21-40 years) and the older age group (⩾ 41 years) were interviewed by general practitioners in their office. Results: In both regions, the majority of subjects had been infected with varicella, and only 165 (5.2%) subjects reported receiving the VZV vaccination. Regarding HZ, 2,749 (86.6%) individuals stated that they knew of the virus and 2,233 (70%) were willing to be vaccinated against HZ. The majority of people willing to be vaccinated were in the middle and older age groups (36.6% and 44.7%, respectively). Conclusion: Compliance versus vaccination results were satisfactory and probably, with the upcoming availability of the HZ vaccine in Italy, adults will be favourably disposed towards vaccination.


Related Articles

  • Herpes zoster vax cost effective in older adults in Belgium?  // PharmacoEconomics & Outcomes News;1/7/2012, Issue 644, p6 

    The article discusses research study on the cost-effectiveness of the varicella zoster virus vaccine Zostavax against herpes zoster in adults aged over 60 years in Belgium. It references a study by J. Bilcke et al published in the November 24, 2011 issue of "Vaccine." The researchers have...

  • Shingles preventive.  // Cortlandt Forum;Sep2006, Vol. 19 Issue 9, p16 

    The article offers information about Zostavax, a varicella-zoster vaccine, manufactured by Merck & Co. Inc. The Zostavax is composed of attenuated vaccine with 19, 400 minimum plaque-forming units per 0.65 milliliter dose. It is designed to prevent herpes zoster in both man and woman aged more...

  • Nowa metoda zapobiegania półpaÅ›cowi i neuralgii popółpaÅ›cowej -- szczepienie szczepem Oka. Wskazania, skuteczność i bezpieczeÅ„stwo szczepienia. Białynicki-Birula, Rafał; Gajdzis, Paweł // Clinical Dermatology / Dermatologia Kliniczna;2007, Vol. 9 Issue 2, p118 

    Herpes zoster (HZ) is caused by reactivation of varicella-zoster virus (VZV) that has been latent in sensory ganglia since primary VZV infection. HZ is mainly a disease of individuals over the age of 60 years and/or immunocompromised patients. Reactivation is a result of a decline in...

  • A varicella-zoster virus vaccine reduced the burden of illness of herpes zoster in older adults. Oxman, M. N.; Levin, M. J.; Johnson, G. R. // Evidence Based Medicine;Dec2005, Vol. 10 Issue 6, p177 

    The article presents a study on the effect of varicella-zoster virus on the burden of illness caused by herpes zoster and the incidence of postherpetic neuralgia in the U.S. Persons 60 years old and below with history of varicella or had lived in the U.S. for 30 years participated in the study....

  • Varicella vaccine efficacy.  // Caribbean Health;Oct2001, Vol. 4 Issue 5, p31 

    The article offers information on the effectiveness of varicella vaccine as treatment for all susceptible people over the age of one year in the U.S. Based from a case-control study conducted in Connecticut, live attenuated varicella vaccine has shown efficacy in medicating all susceptible...

  • RESEARCH BRIEFS: Varicella vaccine effectiveness reduced after first year.  // GP: General Practitioner;2/23/2004, p11 

    This article focuses on a study by U.S. researchers published in the 2004 issue of the "Journal of American Medical Association," according to the which, varicella vaccine effectiveness reduced after first year. Researchers assessed 339 children aged 13 months or older who had been diagnosed...

  • Herpes zoster by reactivated vaccine varicella zoster virus in a healthy child. Uebe, Barbara; Sauerbrei, Andreas; Burdach, Stefan; Horneff, Gerd // European Journal of Pediatrics;2002, Vol. 161 Issue 8, p442 

    Varicella can be prevented by vaccination using the live-attenuated Oka vaccine strain of varicella zoster virus (VZV). Only mild breakthrough disease has been reported in seronegative vaccinees when exposed to the wild-type virus. The latent varicella vaccine virus has rarely caused herpes...

  • Risk for Zoster from the Vaccine in Immunosuppressed Persons. Kuritzky, Louis // Neurology Alert;Sep2012, Vol. 31 Issue 1, p17 

    The article discusses research on the real-life risk of an acute zoster infection after herpes zoster vaccine (ZOS), referencing the study "Risk for Zoster From the Vaccine in Immunosuppressed Persons" by J. Zhang in a 2012 issue of the "Journal of the American Medical Association."

  • Varicella vaccine exhibited long-term efficacy against illness.  // Infectious Diseases in Children;May2013, Vol. 26 Issue 5, p9 

    The article offers information on a study that reveals the efficacy of the varicella vaccine in reducing herpes zoster incidence.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics